Quantcast

Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:
Welcome, Guest. Please login or register.
April 24, 2014, 05:55:01 AM

Login with username, password and session length


Members
Stats
  • Total Posts: 621218
  • Total Topics: 46799
  • Online Today: 229
  • Online Ever: 585
  • (January 07, 2014, 02:31:47 PM)
Users Online
Users: 3
Guests: 182
Total: 185

Welcome


Welcome to the POZ/AIDSmeds Community Forums, a round-the-clock discussion area for people with HIV/AIDS, their friends/family/caregivers, and others concerned about HIV/AIDS.  Click on the links below to browse our various forums; scroll down for a glance at the most recent posts; or join in the conversation yourself by registering on the left side of this page.

Privacy Warning:  Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If you are HIV positive and disclose this in our forums, then it is almost the same thing as telling the whole world (or at least the World Wide Web). If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.

  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.

  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.

  • Forums members must behave at all times with respect and honesty. Posting guidelines, including time-out and banning policies, have been established by the moderators of these forums. Click here for “Am I Infected?” posting guidelines. Click here for posting guidelines pertaining to all other POZ/AIDSmeds community forums.

  • We ask all forums members to provide references for health/medical/scientific information they provide, when it is not a personal experience being discussed. Please provide hyperlinks with full URLs or full citations of published works not available via the Internet. Additionally, all forums members must post information which are true and correct to their knowledge.

  • Product advertisement—including links; banners; editorial content; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from POZ.

To change forums navigation language settings, click here (members only), Register now

Para cambiar sus preferencias de los foros en español, haz clic aquí (sólo miembros), Regístrate ahora

Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Glaxo and Pfizer create new HIV drug company  (Read 574 times)

0 Members and 1 Guest are viewing this topic.

Offline lonewolf

  • Member
  • Posts: 96
Glaxo and Pfizer create new HIV drug company
« on: April 16, 2009, 03:23:33 PM »
Glaxo and Pfizer create new HIV drug company
 

Apr 16, 12:21 PM (ET)

By LINDA A. JOHNSON

TRENTON, N.J. (AP) - Pharmaceutical giants GlaxoSmithKline PLC (GSK) (GSK) and Pfizer Inc. (PFE) (PFE) will pool their resources to create a new company to develop and sell HIV medicines, leveraging a minimal investment into a market-leading position.

The deal, announced Thursday, reflects two key trends sweeping the industry. Companies are narrowing their research areas and cutting costs to improve productivity, and once-ardent competitors are working together to share the risks and costs of developing drugs.

The two companies plan to blend London-based Glaxo's portfolio of HIV drugs now on the market - some with patents approaching expiration - with New York-based Pfizer's more robust pipeline of drugs in development.

With 11 HIV medicines already on sale, the new venture will have a 19 percent market share, ranking it No. 2 behind sales leader Gilead Sciences Inc. (GILD) Other competitors in the field include heavyweights Bristol-Myers Squibb Co. (BMY), Abbott Laboratories (ABT), Merck & Co. (MRK) and DuPont Pharmaceuticals Co.

 
"The combination of a broad current revenue base and a new diverse pool of pipeline assets provides a significant platform to invest in developing and delivering new HIV medicines," Glaxo Chief Executive Andrew Witty said during a conference call with analysts.

The new company's name will be announced when the deal closes, now set for the fourth quarter.

The new company will be based in London and run by longtime Glaxo executive Dominique Limet, who now leads its personalized medicine strategy. The company's U.S. headquarters will be in Research Triangle Park, N.C., where Glaxo's American headquarters are.

Witty told reporters he expects $90 million, or 60 million pounds, in savings - mostly next year - from cutting administration and marketing overlaps. He said research and development operations would be basically unchanged.

The company will have an initial capitalization of about $373 million, or 250 million pounds, 90 percent from Glaxo.

Glaxo will initially hold an 85 percent equity interest in the new company, with Pfizer holding the remaining 15 percent. As time goes by, Witty said, those stakes will grow or dwindle according to which company is producing more successful drugs.

The new company will have several market-leading therapies, including Combivir, Kivexa and Selzentry/Celsentri. Based on 2008 results, the combined portfolio generates sales of around $2.4 billion (1.6 billion pounds).

The companies said revenues at that level will provide the new company with financial stability and support investment in its pipeline. It will contract research and development services directly from Glaxo and Pfizer to develop new medicines.

"We're going to just simply give it enough cash to support its working capital," Witty said. "It's not going to have any debt."

Witty said the new company can then ask its board, which will include seven executives from Glaxo and two from Pfizer, for more funding.

"It's going to have two parents out there with, I think, a very rapid decision-making mechanism to allow it to be funded for what it needs to do," he said.

The two companies said that the new business "will be more sustainable and broader in scope than either company's individually."

"By combining Pfizer's and GlaxoSmithKline's complementary strengths and capabilities, we are creating a new global leader in HIV and reaffirming our ongoing commitment to the treatment of the disease," Pfizer Chief Executive Jeff Kindler said in a joint statement.

The new venture will not include Glaxo's vaccine program, which will continue separately. That's been an area where multiple industry and government projects that looked promising have failed.

The company will have a pipeline of six drugs in human testing, four in mid-stage tests, and a total of 17 experimental compounds.

Shares of Pfizer fell 20 cents to $13.66, while Glaxo slipped 4 cents to $30.79 in New York trading Thursday.

---

"To all within the sound of my voice, I appeal: Learn with me the lessons of history and of grace, so my children will not be afraid to say the word “AIDS” when I am gone. Then, their children and yours may not need to whisper it at all."  Mary Fisher

 


Terms of Membership for these forums
 

© 2014 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.